Dose and dose intensity effect of adjuvant anthracycline-based chemotherapy in early breast cancer -: A retrospective analysis

被引：2

作者：

Amador, ML ^{[1
]}

Jimeno, A ^{[1
]}

Hitt, R ^{[1
]}

Cortés-Funes, H ^{[1
]}

Colomer, R ^{[1
]}

机构：

[1] Hosp Univ Doce Octubre, Dept Med Oncol, Madrid, Spain

来源：

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 2004年 / 27卷 / 03期

关键词：

anthracycline; breast cancer; dose; dose intensity;

D O I：

10.1097/01.coc.0000093082.79608.1a

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The purpose of this study was to determine the importance of the dose of adjuvant chemotherapy in patients with breast cancer, and to determine which variables had influence on the dose of chemotherapy received. We reviewed the records of 196 patients with node-positive breast carcinoma that were treated with anthracycline-based adjuvant chemotherapy. We analyzed the influence on treatment efficacy of the dose of anthracyclines (total dose and dose intensity), and a multivariate analysis was performed to identify independent prognostic factors of chemotherapy total dose, There were no differences in disease-free survival or overall survival between patients who received doses below or above the median total dose and median dose intensity of anthracyclines. A positive correlation was observed between the total dose of anthracycline received and the number of axillary lymph nodes. The clinical outcome of patients with node-positive breast cancer receiving adjuvant anthracycline-based chemotherapy is not affected by the amount of chemotherapy delivered. There exists a clinical practice of administering more chemotherapy in patients with poorer prognosis, which does not result in better therapeutic outcomes.

引用

页码：269 / 273

页数：5

共 20 条

[1]

Abe O, 1998, LANCET, V352, P930

[2] Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors:: 5-year follow-up results of French adjuvant study group 05 randomized trial [J].

Adenis, A ;

Bonneterre, J ;

Bonneterre, ME ;

Pion, JM ;

Vanlemmens, L ;

Gladieff, L ;

de Lafontan, B ;

Martel, P ;

Mihura, J ;

Roché, H ;

Gédouin, D ;

Kerbrat, P ;

Lesimple, T ;

Brémond, A ;

Devaux, Y ;

Delecroix, V ;

Fumoleau, P ;

Maugard-Louboutin, C ;

Namer, M ;

Goudier, MJ ;

Morice, F ;

Montcuquet, P ;

Schraub, S ;

Coudert, B ;

Fargeot, P ;

de Gislain, C ;

Mayer, F ;

Bastit, P ;

Chevallier, B ;

Grandgirard, A ;

Monnier, A ;

Sun, X ;

Clavère, P ;

Ollivier, JP ;

Rhein, B ;

Roullet, B ;

Datchary, J ;

Audhuy, B ;

Barats, JC ;

Kohser, F ;

Dides, S ;

Ramos, R ;

Cattan, A ;

Eymard, JC ;

Pourny, C ;

Weber, B ;

de Laroche, G ;

Pichon, A ;

Seffert, P ;

Hayat, M .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (03) :602-611

[3]

BONADONNA G, 1995, JAMA-J AM MED ASSOC, V273, P542

[4] DOSE-RESPONSE EFFECT OF ADJUVANT CHEMOTHERAPY IN BREAST-CANCER [J].

BONADONNA, G ;

VALAGUSSA, P .

NEW ENGLAND JOURNAL OF MEDICINE, 1981, 304 (01) :10-15

[5]

BONNETERRE J, 1998, AM SOC CLIN ONC ANN

[6] Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer [J].

Budman, DR ;

Berry, DA ;

Cirrincione, CT ;

Henderson, IC ;

Wood, WC ;

Weiss, RB ;

Ferree, CR ;

Muss, HB ;

Green, MR ;

Norton, L ;

Frei, E .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (16) :1205-1211

[7]

COX DR, 1972, J R STAT SOC B, V34, P187

[8]

Daling JR, 2001, CANCER, V92, P720, DOI 10.1002/1097-0142(20010815)92:4<720::AID-CNCR1375>3.0.CO

[9]

2-T

[10] DOXORUBICIN-CONTAINING REGIMENS FOR THE TREATMENT OF STAGE-II BREAST-CANCER - THE NATIONAL SURGICAL ADJUVANT BREAST AND BOWEL PROJECT EXPERIENCE [J].

FISHER, B ;

REDMOND, C ;

WICKERHAM, DL ;

BOWMAN, D ;

SCHIPPER, H ;

WOLMARK, N ;

SASS, R ;

FISHER, ER ;

JOCHIMSEN, P ;

LEGAULTPOISSON, S ;

DIMITROV, N ;

WOLTER, J ;

BORNSTEIN, R ;

ELIAS, EG ;

LICALZI, N ;

PATERSON, AHG ;

SUTHERLAND, CM .

JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (05) :572-582

← 1 2 →